PCSK9 Inhibition to Reduce Cardiovascular Risk: Tempering Expectations

Circ Res. 2017 May 12;120(10):1537-1539. doi: 10.1161/CIRCRESAHA.117.311015.

Authors

David D Waters¹, Priscilla Y Hsue²

Affiliations

¹ From the Division of Cardiology, San Francisco General Hospital, CA; and Department of Medicine, University of California, San Francisco. David.Waters@ucsf.edu.
² From the Division of Cardiology, San Francisco General Hospital, CA; and Department of Medicine, University of California, San Francisco.

PMID: 28495986
DOI: 10.1161/CIRCRESAHA.117.311015

No abstract available

Publication types

Review
Comment

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Cardiovascular Diseases*
Humans
Motivation
Proprotein Convertase 9*
Risk Factors

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
PCSK9 protein, human
Proprotein Convertase 9
evolocumab